| iPSC-Derived Striatal Neurons | |
|---|---|
| Lineage | iPSC > Neural Progenitor > Striatal Neuron |
| Markers | MAP2, DARPP-32, CTIP2, SP8, ISL1 |
| Brain Regions | Striatum - Caudate, Putamen |
| Disease Relevance | Huntington's Disease, Parkinson's Disease, Dystonia |
Ipsc Derived Striatal Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
iPSC-derived striatal neurons are medium spiny neurons (MSNs) and interneurons generated from human induced pluripotent stem cells that model the striatum, the primary input nucleus of the basal ganglia. These neurons express the characteristic marker DARPP-32 (PPP1R1B) and exhibit GABAergic signaling with the electrophysiological properties of authentic medium spiny neurons[1][2].
Striatal differentiation employs patterning factors that specify lateral and medial ganglionic eminence (LGE/MGE) identities:
Express DRD1 (dopamine receptor D1) and project to the substantia nigra pars reticulata (SNr). Activation promotes movement initiation.
Express DRD2 (dopamine receptor D2) and project to the globus pallidus externus (GPe). Activation inhibits movement.
iPSC-derived MSNs from HD patients exhibit:
Striatal neurons model dopaminergic denervation and subsequent:
Patient-derived neurons reveal cellular mechanisms underlying involuntary movements.
Platform for testing compounds that:
Clinical trials are investigating striatal neuron transplantation for Huntington's disease[^5].
The study of Ipsc Derived Striatal Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.